LET'S TALK PLANT MEDICINE: Cannabis, Psychedelics & Pharmaceutics with Dr. O Lola Ohonba

"Dr. Worcester On The Role Of Big Pharma In Cannabis Research & Education For Cancer Pain Management"
Summary/Abstract
Dr. Brooke Worster is the Chief Medical Advisor at Ethios and a cancer pain specialist. She is also a cannabis researcher at Thomas Jefferson University in Pennsylvania. On the show, she discussed her background in pain management and how she got interested in cannabis research. She explained how cannabis is often recommended to her patients, either by their family members, caregivers, or friends. However, the medical community doesn't pay much attention to the positive side of cannabis. She is working to change that and to provide more resources to people interested in cannabis.
Dr. Jeffrey Gendelman discussed his experience with medical cannabis, which began when he felt like he had to respond to patients' questions with I don't know as he had not done much research on the subject. However, when the Pennsylvania legislature passed legislation allowing academic medical centers to partner with vertically integrated growth, production, and dispensing companies, he decided to take the initiative and learn more.
Dr. Gendelman noted the disconnect between patients and providers when it comes to cannabis; patients often feel uncomfortable bringing it up and providers rarely initiate the dialogue due to a lack of knowledge. He believes it's important for doctors, particularly oncologists, to learn how to talk to their patients about cannabis in order to bridge this gap.
The conversation is about how healthcare professionals are not engaging with cannabis as a treatment option. The speaker notes that only a quarter of 10,000 cancer patients feel comfortable talking to their physicians about cannabis. The stigma and hysteria surrounding cannabis have made some patient groups reluctant to even bring up the topic with their physician. The speaker wonders why the medical community has not embraced the potential of cannabis as a therapy, given its long history of use in medicine. He argues that access to and use of cannabis is increasing, and medical professionals must pay attention to it. He also notes that research into the potential of cannabis as a therapy has been limited due to restrictions on its use. The speaker suggests healthcare professionals must become more educated about cannabis and its potential therapeutic uses.
There is not enough education and training available for healthcare professionals to bridge the gap in knowledge around cannabis. This lack of accessible education means that professionals have to do their own research and digging to gain knowledge. It is important to talk to patients and hear their experiences, although it is not the same as a randomized clinical trial. To gain more knowledge and bridge the gap, healthcare professionals should make some noise about the educational gap and try to get more educational outreach and efforts happening.
Timestamps
0:00:06
Conversation with Dr. Brooke Worster, Chief Medical Advisor at Ethios and Cancer Pain Specialist
0:03:01
Exploring the Disconnect between Patients and Providers on Cannabis Use
0:05:30
Exploring the Disconnect Between Clinicians and Cannabis Use in Cancer Patients
0:10:48
Discussion on Accessible Education for Healthcare Professionals on Cannabis Use
0:13:10
Heading: Dr. Worcesters Discusses the Legalization of Medical Cannabis and Dispels the Myth of Losing Licenses
0:16:02
Heading: Discussion on the Role of Big Pharma in Cancer Pain Management with Dr. Worcester
0:20:23
Heading: The Power of Plant-Based Medicines in Treating Cancer Pain and Nausea
0:22:35
Discussion on the Need for Standardized Cannabis Labeling Systems
0:26:13
Conversation on Standardizing Cannabis Information for Patients
0:28:15
Heading: Exploring Cannabis Use in Healthcare: A Conversation with Dr. Worcester
0:30:17
Interview with Dr. Lola Wasa: Exploring the Benefits of Cannabis Medicine
Highlights
Finally, Dr. Worcester, I have another of your quote. You sai

Lumenate is a pioneering app that uses sound and light to change brain rhythms in ways similar to psychedelics and highly experienced meditators, and brain imaging researchers at Imperial College London and as well as researchers in Berlin. 
Our guests have talked about what psychedelic experiences and Lumenate appear to have in common. They talked about Increased brain signal complexity, reduced activity in the default mode network, increased functional connectivity between different brain regions, and reductions in peak alpha brainwaves. 
They have ongoing trials underway in London which "aims to uncover neural mechanisms of visual imagery induced by Lumenate, using high-density EEG. The research also aims at comparing psychedelic experiences induced by DMT and Lumenate, by exploring the psychological and biological mechanisms of both altered states of consciousness”.

Dr. Cornblatt is a Johns Hopkins University School of Medicine Graduate with a Ph.D. in Pharmacology and Molecular Sciences and a postdoctoral fellowship from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology.
Dr. Cornblatt has served as Director of Consumer Clinical Research and Science and as Medical Director at Nutramax Laboratories Consumer Care, Inc. In this role, Dr. Cornblatt developed novel nutraceutical formulations, designed both in vitro and clinical studies in support of products, and summarized both supporting laboratory and clinical research for healthcare workers and consumers.
 His most recent development has been a novel line of products (and 18 related clinical trials) that deliver the essential ingredients needed to support the production of sulforaphane, a phytochemical with many emerging indications. Dr. Cornblatt is also the inventor of three issued patents and four pending provisional patents focused on plant-based bioactive compounds and health promotion.

Silo Pharma merges traditional therapeutics with psychedelic research to develop innovative solutions that address a variety of underserved conditions including Alzheimer’s, Fibromyalgia, Parkinson’s, Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), as well as stress-induced psychiatric disorders (i.e. PTSD) and other debilitating chronic conditions. We talk about the research and the conditions you choose to study in conjunction with psychedelic treatment. 
Silo has partnered with several leading academic institutions (the University of California, San Francisco, Columbia University, and the University of Maryland, Baltimore) to facilitate a streamlined regulatory pathway for drug approval. The company has developed a pipeline of proprietary licensed therapeutics that show promise for a range of illnesses and diseases.
Silo Pharma Inc. has begun dosing in its IND-enabling study of a proprietary time-released, topical formulation of ketamine SP-26 designed to treat fibromyalgia. The safety evaluation trial will be conducted by Experimur, a Frontage Company, and intends to evaluate the tolerability of SP-26 to establish a maximum dose in the treatment of this chronic medical condition causing widespread musculoskeletal pain as well as memory issues, sleep difficulties, and fatigue.

Steven Twohig has been studying an abundance of practices extensively, including mindfulness, business optimization, shadow work and facilitation, Neuro-Linguistic Programming (NLP), hypnotherapy, and leadership dynamics. He recently has been researching psychedelic integration, which is defined as a process in which the patient integrates the insights of their experience into their life, and PHRI is a method of supporting that in the clinical consultation room.
On Steven's website for Mastering Change, he wrote: “miscoding deep in the human mind. This coding is the root cause of all suffering in the world. By doing your shadow work, you are doing the work necessary to change the world. Everything in this reality is a reflection of everything else. If above, so below. So within, so without. You are a reflection of your outside world, just like this world is a reflection of you.” Steven expands on this and much more in today's episode. 

Blake Pearson has been internationally recognized for his work in cannabis medicine and efforts to legitimize cannabinoid therapy as a safer alternative to opioids and anti-psychotic drugs. He has helped improve your patients’ symptoms with cannabinoid medicine and has been able to reduce the anti-psychotics.
Dr. Blake recently announced the start of a new research study into the impact of cannabinoid therapy on local residents with dementia. He has partnered with Lambton College and Steeves & Rozema Nursing Homes for a three-year, $360,000 research grant from the National Sciences and Engineering Research Council of Canada (NSERC). 
We discuss how Dr. Blake feels that this new study is not about healing or halting dementia. It’s about managing the behaviors associated with the disease — such as mood, calling out, agitation, and trouble sleeping.
Blake wrote on his blog about a new placebo-controlled, randomized clinical trial out of Israel published to evaluate the safety and efficacy of broad-spectrum CBD-dominant medical cannabis oil for the reduction of behavioral disturbances amongst patients with dementia. They found a statistically significant reduction in agitation over placebo with non-serious side effects.